Peter Nielsen co-founded Bio-Path Holdings, a public biotechnology company developing targeted oncology therapies, and currently serves as Bio-Path’s president, chief executive officer, chief financial officer and chairman of the board of directors. At the time of Bio-Path’s establishment in 2007, Mr. Nielsen licensed technology and targets from the University of Texas M.D. Anderson Cancer Center and coordinated pre-clinical development, optimization and manufacturing of Bio-Path’s lead product, BP1001. Over the next ten years, Mr. Nielsen led the clinical advancement of BP1001 into Phase 2 studies, the introduction of additional pipeline candidates, and the company’s public market debut. Prior to co-founding Bio-Path, Mr. Nielsen has worked with several other companies, leading turnarounds and developing and executing on strategies for growth. He currently serves as a director of Bio-Path and of Synthecon, Inc., a company developing 3D cell culture technology. Before entering the biotechnology sector, Mr. Nielsen was a lieutenant in the U.S. Naval Nuclear Power program where he was director of the physics department, and was employed at Ford Motor Company in product development. Mr. Nielsen has a broad background in senior management and has significant negotiating experience. He has earned degrees in engineering, mathematics and an MBA in finance from the University of California at Berkeley.
Dr. Ulrich Mueller serves as chief operating officer, having joined Bio-Path in 2014. He was previously a vice president at the Fred Hutchinson Cancer Research Center, one of the leading cancer research institutions in the country, where he was responsible for the institution’s clinical research support and industry relations, including clinical trial and sponsored research agreements, licensing of the institution’s intellectual property and all industry contracts with pharmaceutical companies. Prior to the Hutchinson Center, Dr. Mueller was managing director in the Office of Technology Commercialization at the University of Texas M.D. Anderson Cancer Center, where he was responsible for managing the activities of the Technology Commercialization office including negotiating contract terms for licensing of the institution’s intellectual property. Dr. Mueller holds a doctorate in cell and molecular biology from the Baylor College of Medicine, a Master of Science in biology from Texas A&M University and a Bachelor of Science in microbiology from New Mexico State University.
Dr. Hahne was appointed vice president of clinical research in 2017, in which role he is responsible for the development and implementation of the company's clinical strategic plan, as well as management of ongoing studies, clinical staff, reporting, and budget performance. Prior to joining Bio-Path, he worked as a medical consultant for a number of oncology-focused organizations, before which he held various management- and executive-level positions in clinical research and medical affairs at biotechnology and global pharmaceutical companies including Celator Pharmaceuticals (now a subsidiary of Jazz Pharmaceuticals), Celsion Corp, Glaxo Inc., Hoechst Marion Rousel, and Eisai, Inc. During his career, he has been integrally involved in the design and management of oncology clinical trials, development of key opinion leaders, and growth of clinical departments to meet needs of advancing pipelines. He earned his BA in chemistry from Grinnell College and his MD from Cornell University. He conducted his residency in general surgery at Emory University Affiliated Hospitals in Atlanta, Georgia.
Dr. Ana Tari Ashizawa is a scientific co-founder of Bio-Path Holdings and serves as director of research for the company. Dr. Tari Ashizawa is a leading expert in liposomes, and was instrumental in the development of Bio-Path’s neutral lipid delivery technology. She was previously an associate professor at the University of Texas M.D. Anderson Cancer Center and the University of Florida, Gainesville. Dr. Tari Ashizawa holds a doctorate in biochemistry from the University of Tennessee, and a Master of Business Administration from the University of Florida.
Tara Sadeghi is the director of clinical operations for Bio-Path, and joined the company in April of 2015. Ms. Sadeghi previously served as the assistant director of the Cord Blood Bank Regulatory and Quality Assurance office at the University of Texas M.D. Anderson Cancer Center. She has over 24 years of drug development and clinical operations experience across multiple therapeutic areas, incorporating all phases of clinical development from proof of concept through clinical trials and the submission of Biologics License Applications and New Drug Applications with the U.S. Food and Drug Administration (FDA). A highly skilled team leader, Ms. Sadeghi is experienced in coordinating teams to meet regulatory and organizational requirements. In addition, she has experience in developing liposomal drug formulations for clinical testing, activities very similar to Bio-Path’s core manufacturing technology. Ms. Sadeghi earned a Bachelor of Science from the University of Louisiana at Lafayette.
Dr. Suzanne Kennedy is the company’s director of corporate development and joined Bio-Path in September 2014. She has over 15 years of R&D and business experience in the life science industry in the area of nucleic acid research. Her previous experience at QIAGEN and Thermo Fisher (formerly Invitrogen) in global marketing led to her position as director of research and development for MO BIO Laboratories from 2008 until 2013. In this role she led the development and launch of over 30 products and co-developed the intellectual property leading to two patents as well as established numerous academic and business collaborations for corporate business development worldwide. She received her doctorate from Virginia Commonwealth University in microbiology and immunology in 1997.
Anthony Price serves as the director of finance and accounting. He joined Bio-Path in May 2014 with over 10 years of experience in the healthcare field. From October 2006 through April 2014, he held positions in finance at Lexicon Pharmaceuticals, Inc., most recently as associate director of finance and accounting. From 1993 to 2006, Mr. Price served in a variety of financial and accounting management positions for Building Materials Holding Corporation. Mr. Price holds a Bachelor of Science in business administration - finance from California State University, Fresno and a Master of Business Administration from Colorado State University.
Doug Morris is a co-founder of Bio-Path and a co-founding director. Mr. Morris has a number of administrative responsibilities, including working with retail broker/dealers in raising capital for small cap companies, and interfacing with existing shareholders. Mr. Morris has a Bachelor of Arts from Brigham Young University and a Master of Public Administration from the University of Southern California.
Michael Roberts is the company’s assistant director of manufacturing and supply, and joined Bio-Path in September of 2014. Mr. Roberts brings over 17 years of cGMP lipid manufacturing and liposomal formulation experience. During Mr. Roberts’ previous employment, he worked with Bio-Path’s leadership team on development projects for Bio-Path’s lead drug product. Mr. Roberts received his Bachelors of Science in chemical engineering from the University of Alabama in Huntsville.